Exact Therapeutics As · OSL:EXTX
Exact Therapeutics As — Corporate Update (June 2026)
20 slides from Exact Therapeutics As's corporate update, Jun 4, 2026
Slide 1: Strategic intent to delist from Euronext Growth
EXACT Therapeutics Strategic intent to delist from Euronext Growth Webcast 4 June 2026
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (the "Presentation") has been prepared by EXACT Therapeutics AS (the "Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’re
Slide 3: EXACT Therapeutics Webcast – 4 June 2026
EXACT Therapeutics Webcast – 4 June 2026 Agenda: - Company status and update - Rationale for delisting from Euronext Growth - Anticipated process for the potential delisting - Questions (submitted through the online system) and Answers Presenters: - Anders Wold – Chairman of the Board - Per Walday –
Slide 4: Company status and update
Company status and update =! ACT,
Slide 5: Unlocking Effective Therapies in Solid Tumours
Unlocking Effective Therapies in Solid Tumours We are building a leading biotech company, utilising the power of ultrasound to unlock targeted oncology treatments and improve the lives of cancer patients PS101 solves a core problem in solid tumours: getting enough drug to the cancer cells to drive m
Slide 6: PS101 – aim to increase conversion to resectability in LAPC
PS101 – aim to increase conversion to resectability in LAPC Substantial tumour shrinkage may permit conversion to surgical resectability 30-40% of pancreatic cancer patients Conversion to resection approximately doubles the median overall survival compared with unresected patients1 Borderline resect
Slide 7: ENACT Ph2: Encouraging response to PS101 + standard of care
Presented at company presentation webcast, 11 Feb 2026 ENACT Ph2: Encouraging response to PS101 + standard of care Promising start of ENACT on tumour response Treatment induced decrease in CA 19-9 100 • The first two ENACT patients had ≥85% reduction in CA 19-9 CA 19-9 in % of screening value 75 Ear
Slide 8: Clinical status and update
Clinical status and update Second safety review expected around end-June1 Status – continued good activity across sites with next TMC review expected 1H 2026 • All sites are open for enrolment and 2 out of 3 patients for the 60 µl/kg safety cohort have passed the safety window – the last patient has
Slide 9: Pancreatic cancer: from “undruggable” to actionable
Pancreatic cancer: from “undruggable” to actionable Creating a new opportunity space • RAS breakthrough1 in metastatic pancreatic cancer validates this as a druggable disease • Clear survival benefit → renewed confidence in the RAS biology Delivery & treatment optimisation • Strong field momentum, b
Slide 10: Rationale for delisting from Euronext Growth
Rationale for delisting from Euronext Growth
Slide 11: Not a well-functioning marketplace for EXACT
Not a well-functioning marketplace for EXACT • 50% of trading days in the last 5 years have been without any trades • The listing may not contribute to a reasonable pricing of the shares, as even small or modest trades can lead to large fluctuations in the share price • Positive clinical and regulat
Slide 12: Shareholder composition resembles a private company
Shareholder composition resembles a private company • The composition of the Company’s shareholders highly resembles a private company, where a large percentage of the Company’s shares are held by few shareholders • The largest shareholder holds 39% of the shares, and the 10 and 20 largest sharehold
Slide 13: Limited access to capital through Euronext Growth
Limited access to capital through Euronext Growth Major fundraises ($M) are needed in late-stage clinical development • International VC interactions and advisor feedback strongly suggest that a private setting likely would be a prerequisite for successful financing • The low liquidity and high vola
Slide 14: Anticipated process for the potential delisting
Anticipated process for the potential delisting
Slide 15: Process description
Process description Legal framework: • § 9-30 – Securities Trading Act • Euronext Growth Oslo Rulebook II, §3.17.2(2) • MiFID II Regulations Practical process • The General Assembly makes the decision to authorize the Board to apply for a delisting of a company’s shares from the Oslo Stock Exchange
Slide 16: Timeline for a potential delisting - overview
Timeline for a potential delisting - overview Main activities Notification Last day Call for General Application Decision period of General Assembly to OSE by OSE starts trading – Assembly (3 months) delisted Timeline/dates 29 12 18 ~9 ~9 ~9 Oct Est date: May Jun Jun Jul Jul 16
Slide 17: What does a delisting mean for shareholders?
What does a delisting mean for shareholders? Shareholder’s rights remain unchanged: • You continue to own the same number of shares • Voting rights remain unchanged • Minority shareholder protections under Norwegian company law remain in place Trading platform: • Buying and selling of shares must be
Slide 18: Key take-aways
Key take-aways Focused oncology strategy – positive clinical proof of concept for PS101 Positive start to Phase 2 ENACT trial with 40µl/kg dose; 60µl/kg dose well underway Planning for success - new capital market strategy to facilitate future potential VC funding General Assembly scheduled for 12 J
Slide 19: Q&A
Q&A =! ACT,
Slide 20: Contacts
Contacts Contacts Dr Per Walday CEO E: per.walday@exact-tx.com John M. Edminson CFO E: john.edminson@exact-tx.com